Recent reports showed that ovarian cancer cells that acquired CR expressed high levels of mitogen-activated protein kinase phosphatase-1 (MKP-1) and PARP-1 proteins; hence, silencing MKP-1 or PARP-1 increases cisplatin sensitivity in resistant cells. This evidence concerns the gene PARP1 and ovarian carcinoma.